<DOC>
	<DOC>NCT02073279</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic and immunogenic profiles of SA237 in patients with NMO and NMOSD</brief_summary>
	<brief_title>Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD</brief_title>
	<detailed_description />
	<mesh_term>Neuromyelitis Optica</mesh_term>
	<criteria>1. NMO or NMOSD 2. Age 18 to 74 years, inclusive at the time of informed consent. 1. Pregnancy or lactation. 2. Evidence of other demyelinating disease or PML. 3. Known active infection (excluding fungal infections of nail beds or caries dentium) within 4 weeks prior to baseline.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>